RNXT
RenovoRx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$39.75M
P/E Ratio
—
EPS
$-0.33
Beta
1.00
52W High
$1.45
52W Low
$0.70
50-Day MA
$0.94
200-Day MA
$1.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.
Fundamentals
| Revenue (TTM) | $1.49M |
| Gross Profit (TTM) | $1.17M |
| EBITDA | $-12.37M |
| Operating Margin | -616.00% |
| Return on Equity | -100.50% |
| Return on Assets | -51.60% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $0.25 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 26.70 |
| EV/Revenue | 18.52 |
| EV/EBITDA | -4.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 185.80% |
| Shares Outstanding | $45.10M |
| Float | $39.90M |
| % Insiders | 3.77% |
| % Institutions | 19.01% |
Historical Volatility
HV 10-Day
61.73%
HV 20-Day
53.67%
HV 30-Day
52.40%
HV 60-Day
65.98%
HV Rank
23.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.91 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026